Open access · US-GOV via ClinicalTrials.gov Clinical trial

First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients

Authors not listed

Pharnext S.C.A. · 2013

Dysbiosis Human Randomized controlled trial

Abstract

The purpose of this study is to assess the safety and efficacy on cognitive impairment and functioning of several doses of PXT00864 (new fixed combination of acamprosate and baclofen at low dose) in patients with mild Alzheimer Disease.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-19 MST

Cite this

APA

Anonymous. (2013). First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients. <em>Pharnext S.C.A.</em>. https://clinicaltrials.gov/study/NCT02361424

Vancouver

Anonymous. First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients. Pharnext S.C.A.. 2013.

BibTeX

@misc{anon2013FirstS, title = {First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients}, author = {Anonymous}, journal = {Pharnext S.C.A.}, year = {2013}, }